1 Alterations in the plasma metabolome associated with maternal

- 2 smoking during the first trimester
- 3 Wadzanai Masvosva¹, Taija Voutilainen¹, Marko Lehtonen¹, Retu Haikonen², Seppo
- 4 Auriola¹, Leea Keski-Nisula^{3,4}, Jaana Rysä¹, Olli Kärkkäinen¹
- 5

6 Affiliations:

- 7 ¹ School of Pharmacy, University of Eastern Finland
- 8 ²Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio,
- 9 Finland
- ³Institute of Clinical Medicine, School of Medicine, University of Eastern Finland, Finland
- ⁴Department of Obstetrics and Gynecology, Kuopio University Hospital, Finland

12

- 13 Correspondence: Dr. Olli Kärkkäinen, School of Pharmacy, University of Eastern Finland,
- 14 Yliopistonrinne 3, 70210 Kuopio, Finland; olli.karkkainen@uef.fi

15

16 Plain language summary

- 17 Tobacco smoking during pregnancy has been associated with an increased risk of adverse
- 18 outcomes like low birth weight. In this study, we measured changes in the circulating
- 19 metabolome linked to maternal smoking in the first trimester and correlated these
- 20 changes to the growth of the fetus. Maternal smoking during the first trimester of
- 21 pregnancy was associated with an altered metabolite profile linked to endocrine disruption
- 22 and increased oxidative stress. Furthermore, some these changes were associated with
- 23 reduced growth of the fetus.

24 Abstract

Tobacco smoking during pregnancy has been associated with an increased risk of adverse 25 outcomes like low birth weight. This study determined changes in the circulating 26 metabolome linked to maternal smoking in the first trimester and correlated these 27 changes to the growth of the fetus. The circulating metabolome was examined from first 28 29 trimester plasma samples by non-targeted liquid chromatography mass spectrometry based metabolite profiling of 227 pregnant women (99 smokers and 117 non-smokers) 30 from the Kuopio Birth Cohort Study. Tobacco smoking was self-reported through a 31 guestionnaire and verified with cotinine measurements from plasma samples. In summary, 32 64 significant differences were observed between the groups after correction for multiple 33 testing e.g. in metabolites indicating endocrine disruption (e.g., dehydroepiandrosterone 34 sulfate [DHEA-S], VIP=2.70, d=0.68, p<0.0001), metabolites associated with oxidative stress 35 (e.g., bilirubin, VIP=2.00, d=0.50, p<0.0001) and lipid metabolism (e.g., LysoPC 16:1, 36 37 VIP=2.07, d=0.51, p<0.0001). Some of these metabolites, e.g., DHEA-S and bilirubin, correlated with low birth weight, and some, e.g. LysoPC 16:1, correlated with small head 38 circumference at birth. In conclusion, maternal smoking during the first trimester of 39 pregnancy was associated with an altered metabolite profile linked to endocrine disruption 40 and increased oxidative stress. 41

42 **Keywords:** tobacco, smoking, pregnancy, metabolome, metabolomics

43

44

45 Introduction

Smoking has been recognized as the most important preventable cause of mortality in the world¹. Approximately 10% of women worldwide smoke during pregnancy, although the rate varies greatly between regions and countries². Smoking during pregnancy exposes the fetus to the harmful effects of tobacco.

50

Nicotine is the main psychoactive ingredient in tobacco, and it can easily cross the placental 51 barrier. Nicotine concentrations in fetal circulation have been reported to be even 15% 52 higher than those detected in the maternal circulation³. Nicotine causes a general 53 constriction of blood vessels, decreasing the delivery of nutrients to the developing fetus. 54 Carbon monoxide is another harmful chemical present in tobacco smoking; it binds avidly 55 to hemoglobin and subsequently reduces the amount of oxygen being carried to the fetus 56 thus increasing the risk for hypoxia⁴. During pregnancy, even low levels of tobacco smoking 57 have been associated with an increased risk of adverse outcomes like low birth weight⁵, 58 sudden infant death syndrome⁶, behavioral and neurodevelopmental impairments⁷ and 59 asthma and obesity⁸. The effects of maternal tobacco smoking during pregnancy may be 60 permanent and not just be evident from childhood but also last into adulthood, for 61 example, leading to elevated blood pressure, endothelial dysfunction, and even changes in 62 renal structure⁹. 63

64

65	Only a limited number of studies have investigated changes in the metabolite profile
66	associated with smoking during pregnancy. Gray et al. (2010) observed metabolic
67	differences in the umbilical venous samples taken at birth between smoking exposed and
68	non-exposed neonates ¹⁰ . For example, they reported lower concentrations of
69	lysophosphatidylcholine (LysoPC) 16:0, LysoPC18:0, and LysoPC 18:1 in the umbilical
70	venous samples from smoking exposed newborns. Indeed, low lysophosphatidylcholine
71	levels have been associated with a lowered birth weight in the newborns ¹¹ . Furthermore,
72	Rolle-Kampczyk et al. (2016) examined the impact of maternal smoking on endogenous
73	metabolites in 40 maternal and umbilical blood samples. They revealed significant
74	alterations in several metabolites, including sphingomyelin SM 26:0 and several
75	phosphatidylcholines (PCs), in both mothers and children within the smoking-exposed
76	group ¹² . In their evaluation of urine samples from the first and second antenatal visit of
77	105 pregnant Afro-American women, Tan et al. (2022) revealed that 47 metabolites that
78	have been linked with increased inflammation and decreased oxidation of amino acids
79	were associated with high cotinine levels. These detected metabolites also have potential
80	health-related effects during gestation with the possibility to influence several
81	pathophysiological pathways causing adverse birth outcomes ¹³ . However, to our
82	knowledge, there have been no studies investigating tobacco smoking associated
83	alterations in the metabolite profiles during the first trimester, which is a crucial time
84	during pregnancy since it is the period of organogenesis ¹⁴ .

86	Therefore, here we wanted to examine the changes in the maternal metabolome
87	associated with smoking in the first trimester to increase our understanding of the
88	metabolic consequences of gestational smoking. In this nested case-control study, our aim
89	was to identify cigarette smoking-induced changes in the circulating metabolome by
90	applying a non-targeted metabolomics approach in the evaluation of first trimester plasma
91	samples of women in the Kuopio Birth Cohort (KuBiCo). In addition, we aimed to
92	investigate how these changes in the metabolome could be associated with fetal growth.
93	
94	Methods
95	Study Cohort.
96	This study is part of Kuopio Birth Cohort (KuBiCo), which is a joint research effort between
97	the University of Eastern Finland (UEF), Kuopio University Hospital (KUH), and National
98	Institute for Health and Welfare (THL) ¹⁵ . The KuBiCo study was approved by the Research
99	Ethics Committee, Hospital District of Central Finland in 15.11.2011 and all participants
100	have given their written electronic consent. The study was conducted in accordance with
101	the Basic & Clinical Pharmacology & Toxicology policy for experimental and clinical
102	studies ¹⁶ .
103	

The cohort consists of women from Finnish Northern Savo county expected to have
delivery at KUH. The participants were recruited during their first trimester routine
antenatal visit by a health care nurse, during weeks 6-9 of gestation mainly from the

107	outpatient maternity clinics. Additionally, these women filled in several questionnaires
108	which evaluated their background risk for ongoing pregnancy in the Pikku-Haikara system
109	designed in the Kuopio University Hospital for pregnant women. The information on
110	gestational smoking/tobacco exposure was gathered via standardized questionnaires.
111	Between the years 2012 and 2020, approximately 5000 first trimester plasma samples were
112	collected routinely for the KuBiCo study at the same time with the first trimester fetal
113	screening samples. This study utilizes these collected first trimester plasma samples, which
114	were kept at -80°C until the metabolomics analysis ¹⁵ .
115	
116	To allow the samples to be used for this study, the subjects of interest should be pregnant
116 117	To allow the samples to be used for this study, the subjects of interest should be pregnant with a parity of six or less, with the preference to use samples from their first pregnancies.
116 117 118	To allow the samples to be used for this study, the subjects of interest should be pregnant with a parity of six or less, with the preference to use samples from their first pregnancies. Participants' self-reported tobacco use gathered in an online questionnaire was used to
116 117 118 119	To allow the samples to be used for this study, the subjects of interest should be pregnant with a parity of six or less, with the preference to use samples from their first pregnancies. Participants' self-reported tobacco use gathered in an online questionnaire was used to evaluate tobacco smoking during pregnancy ¹⁷ . Tobacco smoking was defined as taking any
116 117 118 119 120	To allow the samples to be used for this study, the subjects of interest should be pregnant with a parity of six or less, with the preference to use samples from their first pregnancies. Participants' self-reported tobacco use gathered in an online questionnaire was used to evaluate tobacco smoking during pregnancy ¹⁷ . Tobacco smoking was defined as taking any tobacco products after conception. There was no limitation on the number of cigarettes
116 117 118 119 120 121	To allow the samples to be used for this study, the subjects of interest should be pregnant with a parity of six or less, with the preference to use samples from their first pregnancies. Participants' self-reported tobacco use gathered in an online questionnaire was used to evaluate tobacco smoking during pregnancy ¹⁷ . Tobacco smoking was defined as taking any tobacco products after conception. There was no limitation on the number of cigarettes smoked per day. The smokers were compared against controls who recorded not having
116 117 118 119 120 121 122	To allow the samples to be used for this study, the subjects of interest should be pregnant with a parity of six or less, with the preference to use samples from their first pregnancies. Participants' self-reported tobacco use gathered in an online questionnaire was used to evaluate tobacco smoking during pregnancy ¹⁷ . Tobacco smoking was defined as taking any tobacco products after conception. There was no limitation on the number of cigarettes smoked per day. The smokers were compared against controls who recorded not having smoked at all during pregnancy. Since it is evident that self-reported data is not 100%
116 117 118 119 120 121 122 123	To allow the samples to be used for this study, the subjects of interest should be pregnant with a parity of six or less, with the preference to use samples from their first pregnancies. Participants' self-reported tobacco use gathered in an online questionnaire was used to evaluate tobacco smoking during pregnancy ¹⁷ . Tobacco smoking was defined as taking any tobacco products after conception. There was no limitation on the number of cigarettes smoked per day. The smokers were compared against controls who recorded not having smoked at all during pregnancy. Since it is evident that self-reported data is not 100% reliable, we initially selected more controls than tobacco smokers. After liquid

125 control group as they had elevated levels of nicotine or cotinine in their blood sample.

126 This led to the selection of two study groups: a control group with 117 samples of women

127 who had not smoked during pregnancy and a study group with 99 samples of women who

128	had smoked during their pregnancy but did not report any alcohol use during pregnancy.
129	We excluded alcohol users, since alcohol use during pregnancy is more common in those
130	who smoke and is known to influence the metabolome during pregnancy ¹⁸ . The analysis
131	order of the samples was randomized using a random number generation algorithm.
132	
133	This study used the following descriptive characteristics collected from the KUH birth
134	registry: maternal age, height and weight, body mass index (BMI; kg/m²), parity, gravidity,
135	duration of pregnancy at birth, length of maternal hospital stay after birth, relationship
136	status, and in the smoking women, the daily amount of cigarettes before and during
137	pregnancy to allow the estimation of the smoking index. Additionally, in the newborns, data
138	was collected on gender, birthweight, head circumference, placental weight, APGAR scores
139	(1 and 5 minutes), need for special or neonatal intensive care, ventilation assistance or
140	intubation, need for postnatal antibiotic treatment or phototherapy, and the presence of
141	any congenital malformations.
142	

143 Non-targeted LC-MS based metabolite profiling

The metabolomics analysis was performed according to previously released guidelines with some modifications¹⁹. In brief, sample preparation was done by thawing plasma samples in ice-cold water; the samples were maintained in ice-cold water during all waiting periods before they were transferred for sample preparation into 96 well plates (Thermo Scientific

148	Nunc) embedded on wet ice and covered with a filter plate (Captiva ND filter Plate 0.2 um
149	PP 5/pk, Part no. A5969002, 732-2669). Then, 320 μ L of cold acetonitrile (HPLC LC-MS Grade
150	83640.320, VWR) were dispensed into the filter plate well. The plasma samples were then
151	vortexed for 10 seconds at maximum speed and subsequently 80 μ L of the plasma
152	samples were added to the same well with acetonitrile. The Andrew Alliance robot with a
153	Microplate shaker (519.4004.14HAK, Vacuum + 518.6093.160UY, 8-ch 1200) was used for
154	sample preparation. Preparation of the quality control sample (QC) was done by adding 10
155	μL of each sample to the same clean microcentrifuge tube and mixing. These QC samples
156	were injected at the beginning of the analysis to stabilize the liquid chromatography (LC)
157	column. QC samples were also tested after every 12 th sample in the analysis runs to assess
158	batch and drift correction and data quality analysis, as well as in the tandem mass
159	spectrometry analyses. The samples were precipitated by centrifuging the plate for 5
160	minutes at 700xg at 4 °C after which, the filter plate was sealed tightly to avoid sample
161	evaporation prior to the following metabolomics analysis
162	
163	The metabolomics analysis used ultrahigh performance liquid chromatography (UPLC) with
164	a Thermo Q Exactive Hybrid quadrupole-orbitrap mass spectrometer (MS). Samples were
165	analyzed using two chromatographic techniques, reversed phase (RP) and hydrophilic
166	interaction (HILIC), in both positive and negative polarities. The RP chromatography column
167	was Zorbax Eclipse XDB-C18. The mobile phase A was H2O + 0.1 % HCOOH, mobile phase B
168	was MeOH + 0,1 % HCOOH with a 16.5 min gradient and a flow rate of 0.4 ml/min. The

169 HILIC chromatographic set-up used an Acquity BEH amide column, Mobile phase A: 50%

170 Acetonitrile + 20 mM ammonium formate buffer, B: 90 % acetonitrile + 20 mM ammonium

171 formate buffer, 12.5 min gradient, 0,6 ml/min.

Both negative and positive electrospray ionization (ESI) were used in both analytical modes.

173 ESI settings were ray voltage 3.5 kV for positive and 3.0 kV for negative, max spray current

174 100, flow rates 40 for sheath gas, 10 for auxiliary gas, and 2 for spare gas (as arbitrary units

175 for ion source), S-lens RF level 50 V, capillary and probe heater temperature 300 °C. A full

scan range from m/z 60 to 700 in the HILIC modes and 120 to 1200 in the RP modes with a

resolution of 70 000 (m/Δm, full width at half maximum at 200 u) and an automated

injection time and gain control targeted at 1 000 000 ions. In the tandem mass

spectrometry (MS/MS), three peaks with apex triggers ranging from 0.2 up to 3 s were

selected for MS/MS fragmentation with 15 s dynamic exclusion. A normalized collision

energy at 20, 30, and 40%, was used in MS/MS with a mass resolution of 17 500 (m/ Δ m, full

182 width at half maximum at 200 u), an automated gain targeted at 50 000, and an isolation

183 window of 1.5 m/z.

184

Data analysis was done using MS-dial software 4.90 version for peak picking, peak alignment, and metabolite identification. Data collection had an MS1 tolerance of 0.005 and an MS2 tolerance of 0.025. The retention time for parameters started at 0.5 minutes and stopped at 100 minutes with a mass range and MS/MS mass range of 50 Da up to 2000 Da. Peak detection parameters had a minimum peak height of 300,000 with an amplitude smoothing level of 3 scans, minimum peak width of 8 scans, and a mass slice width of 0.1 Da. Deconvolution parameters had a sigma window value of 0.5 with 0 as the amplitude

192	cut-off. The identification was performed against the University of Eastern Finland in-house
193	database with accurate mass tolerance of MS1 0.008 Da and MS2 0.025 Da. Automatic
194	identifications were verified and corrected manually. Adduct ion settings of [M+H]+,
195	[M+NH4]+, [M+Na]+, [M+K]+, [M+Li]+, [M+ACN+H]+, [M+H-H2O]+, [M+H-2H2O]+, [2M+H]+
196	were utilized in positive polarity and [M-H]-, [M-H2O-H]-, [M+Na-2H]-, [M+Cl]-, [M+FA-H],
197	[M+Hac-H]-, [2M-H]- when we applied negative polarity. The alignment parameters settings
198	had a retention time of 0.05 mins with MS1 tolerance 0.015 for molecular features detected
199	in at least 30% of the samples in one of the groups with a gap-filling by compulsion.
200	
201	Preprocessing of the data (data quality analysis, drift and batch effect correction,
202	imputation of missing values), and statistical analyses were done using the R-package
203	notame ¹⁹ .
204	
205	The identification of metabolites focused on those molecular features with p-values <0.05.
206	The molecular features were grouped into 4 levels according to the community
207	guidelines ²⁰ . Level 1 identification included those compounds confirmed by matching to
200	

209 standards from the in-house library. Level 2 identification comprised putatively annotated

- 210 compounds, identified by matching to exact mass and MS2 spectra against public libraries.
- 211 Level 3 identification referred to the compounds identified at the chemical group level but
- lacking an exact compound identification, while level 4 consisted of unknown compounds.

213 <u>Statistical analysis.</u>

Differences between background characteristics were evaluated with Welch's t-test and 214 215 Chi² test. With respect to the metabolomics data, univariate analysis was done with Cohen's d effect sizes with p-values being calculated using Welch's t-test. Since molecular features 216 in metabolomics analysis are not independent, the number of principal components 217 218 needed to explain 95% of the variance in the metabolomics data in the principal component analysis (PCA) was used and to account for multiple testing the Bonferroni 219 method was applied. Here, 184 PCs were needed to explain 95% of the variation in the 220 metabolomics data, therefore the α level was adjusted to 0.0003. Findings with p-values 221 between 0.05 and 0.0003 were considered to be trends. Additionally, we used partial-least-222 squares discriminant analysis (PLS-DA) to identify the variables that contributed most 223 224 extensively to the variation between smoking and nonsmoking pregnant women in a multivariate analysis. Cross-validation was done by splitting the dataset into 7 subsets. 225 226 Variable importance to the projection (VIP) values from PLS-DA are reported for each variable. Correlations between molecular features and birth weight or head circumference 227 were calculated using linear regression. We used SIMCA 17.0 for multivariate data analysis 228 solution, whereas we utilized the notame (version 0.3.0) R-package for the calculation of 229 univariate statistics for metabolomics data¹⁹. JASP (version 0.17) software was used to 230 calculate statistics related to the background characteristics between the non-smoking and 231 smoking groups. Figures were made using Prism (GraphPad software Inc. version 10.0) and 232 SIMCA version 17.0. 233

234 Results

- 235 The characteristics of the pregnant women and their newborns women are shown in Table
- 1. Smokers had a significantly lower parity, higher BMI values, pre-pregnancy weights and
- 237 were less likely to be in a relationship when compared to the nonsmoking controls. On
- average, the newborns of smokers had a lower birth weight and head circumference when
- 239 compared to control newborns. Furthermore, they needed more antibiotic therapy and
- treatment in the intensive care unit than the controls.
- 241
- 242
- 243 **Table 1:** Background characteristics of the study women.

Maternal characteristics					
	Controls	n=117	Cases n=99		p value
Maternal age (years, mean; ±SD)	28.4	±5.7	27.4	±5.7	0.192 ^ª
Maternal height (cm, mean; ±SD)	163.9	±5.6	165.3	±5.5	0.077 ^a
Maternal weight, kg	64.2	±14.0	69.5	±13.8	0.006 ^a
(pre-pregnancy) (mean; ±SD)					
Maternal BMI kg/m2	23.8	±4.9	25.5	±5.1	0.020 ^a
(mean; ±SD)					
Parity (N, mean; SD)	1.7	±2.2	1.2	±1.2	0.026 ^a
Gravidity (N, mean; SD)	3.3	±2.8	3.1	±1.9	0.522 ª
Duration of pregnancy at birth (days, mean; SD)	278	±11	277	±15	0.566 ^a
Hospital stay after birth, days (mean; SD)	3.3	±1.7	3.7	±2.7	0.152 ^a
ln a relationship (n, %)	108	92%	62	63%	<0.0001 ^b

Cigarettes per day before pregnancy	0	±0	15.2	±6.3	<0.0001 ^a
(mean; ±SD)					
Cigarettes per day	0	±0	6.3	±4.0	<0.0001 ª
during pregnancy					
(mean; ±SD)					
Smoking Index	0	±0	2.4	±0.9	<0.0001 ^a
(mean; SD)					
Characteristics of the r	newborns			1	
Female (n, %)	57	49%	43	43%	0.438 ^b
Birth weight (g, mean	3552	±513	3397	±534	0.032
±SD)					
Head circumference	35.2	±1.4	34.7	±1.6	0.020 ª
(cm, mean; ±SD)					
Placenta weight	618.6	±141.4	605.5	±135.0	0.489 ^a
(grams, mean; ±SD)					
APGAR scores 1 min	8.8	±1.0	8.	±1.1	0.615ª
(mean; ±SD)					
APGAR scores 5 min	8.9	±1.3	9.0	±0.8	0.611ª
(mean; ±SD)					
Child's special care	13	11%	21	21%	0.042 ^b
after birth (n, %)					
Need for treatment	10	8.5%	21	21%	0.008 ^b
in Neonatal Intensive					
Care Unit (n, %)					
Ventilation assistance	0	0%	1	1%	0.276 ^b
(n, %)					
Intubation (%)	0	0%	1	1%	0.276 ^b
Postnatal antibiotic	4	3.4%	13	13.1%	0.008 ^b
treatment (n, %)					
Phototherapy (%)	5	4.3%	5	5%	0.787 ^b
Malformations (%)	1%	0.9%	0	0%	0.357 ^b

244 Legend: ^a Welch's t test; ^b Chi² test.

245

247	A total of 9600 molecular features were observed in the non-targeted metabolomics
248	analysis (Supplementary table 1). The PCA analysis revealed that 184 principal components
249	were required to explain 95% of the overall variance in the metabolomics data. These
250	results were used to adjust the α level to 0.0003 to account for multiple testing using
251	Bonferroni correction after which a total of 1109 molecular features had a p-value < 0.05,
252	and 193 molecular features had a p-value < 0.0003 (Figure 1). The PLS-DA model also
253	revealed a difference between the first trimester plasma samples of nonsmokers and
254	smokers (6 components, cum R2Y = 0.99, Q2 = 0.70) (Figure 1, Supplementary table 1).
255	
256	Our results showed that the circulating metabolite profiles from the first trimester plasma
257	samples of smoking pregnant women were different from the nonsmoking controls (Figure
258	1). The identified metabolites were grouped according to the human metabolome database
259	(HMDB) ²¹ . For example, smokers had significantly lower levels of bilirubin and biliverdin,
260	and significantly higher levels of dehydroepiandrosterone sulfate (DHEA-S) (Figure 2). High
261	levels were also evident for several exogenous compounds e.g. cotinine, nicotine, and
262	trigonelline along with xanthines like caffeine, paraxanthine, and theophylline in the
263	smokers when compared to the controls.

264

The correlation analysis indicated that birth weight was also positively associated with the levels of biliverdin (r = 0.20, p = 0.0029), creatine (r = 0.15, p = 0.0029) and PC38:6

- 267 (16:0_22:6) (r = 0.14, p = 0.0035) and negatively associated with those of cotinine (r = -0.18,
- 268 p = 0.00096), Asp-Phe (r-0.15, p = 0.0026), DHEA-S (r = -0.15, p = 0.0265) and AC14:1 (r =-
- 269 0,13, p = 0.0049). Head circumference was negatively associated with the levels of 7a-
- 270 hydroxy-3-oxo-4-cholestenoic acid (r = -0.18, p=0.001), cotinine (r = -0.17,p=0.0013), LysoPC
- 271 16:1 (16:1/0:0) (r = -0.16, p = 0.0019), LysoPC 16:1 (0:0/16:1) (r = -0.15, p = 0.0028), AC 06:0 (r
- 272 = -0.15, p = 0.0037) and lenticin (r = -0.14, p = 0.0043). These results are shown graphically
- in Figure 3 and Figure 4.



275

276 Figure 1: Overview of metabolite profiling from the first trimester maternal plasma samples. A total of 9600 molecular features were observed from the chosen samples. Panel 277 A shows the outcomes of the principal component analysis (PCA). A total of 184 278 components were needed to account for 95% of the variance in the data. PC1 (t1) explained 279 4.5 % of the variation in the data, and PC2 (t2) explained 4.3% of the data. Panel **B** shows 280 partial least squares discriminant analysis (PLS-DA) which illustrates the good separation 281 between the study groups (6 components, cum R2Y = 0.99, Q2 = 0.70). Panel **C** shows the p 282 values (Welch's t-test), Cohen's d effect sizes, and VIP values from the PLS-DA) of all of the 283 relevant molecular features. A total of 193 molecular features were significantly altered 284 between the smokers' and nonsmokers' samples (adjusted α level= 0.0003, Bonferroni's 285 286 correction).



Figure 2: Smokers show altered metabolite profile in the first-trimester plasma samples when compared to nonsmoking controls. Box plots with whiskers (min and max) are shown with p-value from a Welch's t-test (multiple testing adjusted α level was 0.0003). Biliverdin result should be considered a trend. Abbreviations: DHEA-S, dehydroepiandrosterone sulfate; PC, phosphatidylcholine.



289

Figure 3: Association between the birth weight of the newborn and metabolite levels in thefirst trimester of pregnancy. Three metabolites were positively associated with birth weight

- and four were negatively associated with birth weight. Abbreviations: AC 14.1:
- 293 tetradecenoylcarnitine; Asp_Phe: Aspartyl-phenylalanine; PC: phosphatidylcholine; p: p-
- 294 value, r: Pearson correlation coefficient



296

297

- **Figure 4:** Correlations between the head circumference of the newborn and first trimester
- levels of metabolites. Six metabolites were negatively associated with differences in the
- 300 head circumference between the groups. Abbreviations: AC 06:0, Hexanoylcarnitine;
- 301 LysoPC: lysophosphatidylcholine, p: p-value, r: Pearson correlation coefficient

303 Discussion

304

305	We demonstrated that the profiles of the first trimester circulating metabolites of smoking
306	pregnant women were different from those of non-smoking controls. Furthermore, some
307	of these differences were associated with the known unfavorable effects of smoking such
308	as low birth weight and smaller head circumference. Key differences in the metabolite
309	profiles of smoking pregnant women were detected in several factors e.g., elevated levels
310	of DHEA-S and reduced levels of bilirubin and ergothioneine, as well as in certain specific
311	small molecules which are linked directly to the tobacco smoking (nicotine, cotinine, 3-
312	hydroxypyridine) and a higher coffee intake (caffeine, paraxanthine, trigonelline). This
313	finding is in line with the published literature that there is an association between higher
314	nicotine/ cotinine levels and unfavorable fetal/ neonatal effects like low birth weight ²² .
315	However, this study expands these findings by linking also other metabolites such as
316	DHEA-S and bilirubin to fetal and neonatal growth.
317	

We found that pregnant women who were smokers had high levels of DHEA-S in the first
trimester plasma samples, and that these were further associated with the lower birth
weight. DHEA-S is as a metabolic intermediate in the biosynthesis of sex steroids ²³.
Smoking has been shown to influence adrenal hormone production by upregulating the
adrenal β-arrestin 1 enzyme, which is involved in the development of hyperaldosteronism
and consequently to higher basal levels of DHEA-S^{24,25}. The elevated DHEA-S levels are
evidence of an endocrine disorder attributable to maternal smoking and it has been

reported that endocrine disturbances can be linked to growth retardation and neurological
 impairments in the newborn²⁶.

327

328	Moreover, smokers displayed lowered plasma levels of ergothioneine, which is a
329	microbiota-associated antioxidant. Earlier studies have shown that low levels of
330	ergothioneine during pregnancy are associated with negative pregnancy outcomes like pre-
331	eclampsia ²⁷ . Conversely, high ergothioneine levels are associated with health benefits like
332	protection against cardiovascular diseases ²⁸ , and this seems to be the case for biliverdin
333	and bilirubin ²⁹ , implying that this protective mechanism has become impaired in smokers.
334	Smokers had low levels of two endogenous antioxidant biomarkers i.e., bilirubin and
335	biliverdin, when compared to the controls, a finding which is in line with previous
336	reports ^{30,31} . Biliverdin is a metabolite formed from the breakdown of hemoproteins; it is
337	further reduced to bilirubin by biliverdin reductase ³² . Low levels of bilirubin have been
338	associated not only with smoking-related respiratory diseases ³⁰ , but also with autoimmune
339	diseases like lupus and rheumatoid arthrtis ³³ . Thus, the low levels ergothioneine, biliverdin
340	and bilirubin indicate that the pregnant women who smoke have a reduced antioxidative
341	capacity while being subjected to increased oxidative stress; these types of changes could
342	well trigger unfavorable outcomes like growth restrictions ⁵ . In line, we observed that the
343	presence of low biliverdin levels in the first trimester plasma samples was associated with
344	low birth weights in the newborns.

345

346	Additionally, our study showed a lower abundance of isatin (1H-indole-2,3-dione) in the
347	smoking group when compared to the control group. The levels of $$ isatin have been
348	reported to be lower in smokers due to the impact of monoamine oxidase activity and
349	oxidative stress since monoamine oxidase is the enzyme that metabolizes isatin ³⁴ . An
350	increased level of oxidative stress has been reported to alter the regulation of isatin in the
351	body, where it acts as a neuroprotective agent ³⁵ . It would be enlightening to clarify if low
352	isatin levels would be associated with neurological impairments in newborns.

353

Moreover, the metabolomics analysis also showed that the levels of three metabolites linked to tobacco smoking, namely nicotine, cotinine, 3-hydroxypyridine, were significantly increased in blood samples of the tobacco-exposed mothers. Here, cotinine exhibited a significant negative correlation to birth weight and head circumference. Interestingly, previous studies have shown that the metabolism of nicotine is accelerated during pregnancy; this was assessed by measuring the nicotine metabolite ratio at different gestational weeks³⁶.

361

Furthermore, the observed high levels of metabolites associated with caffeinated products (caffeine, theophylline, paraxanthine and trigonelline) are in line with previous studies that found that smoking pregnant women consume more caffeinated products compared to their nonsmoking pregnant counterparts³⁷. It is recognized that the metabolism of compounds present in coffee is reduced during pregnancy³⁸, and additionally, after

367	crossing the placental barrier, caffeine's metabolism is decreased possibly leading to		
368	prolonged effects in the fetus ³⁹ . Previously, an increased coffee intake has been associated		
369	with a low birth weight 40 , although here we did not observe correlations between birth		
370	weight and the levels of coffee metabolites.		
371			
372	Additionally, we detected significant alterations in the concentrations of lipids; higher levels		
373	(e.g., LysoPC 16:1), and lower levels (e.g., PC 38:6) in the tobacco smoking group.		
374	Disturbances in lipid levels have been associated with negative developmental effects in		
375	the newborns' brains and retinas ⁴¹ . Also here, the high levels of LysoPC 16:1 were		
376	associated with a small head circumference whereas low levels of PC 38:6 were linked with		
377	a reduced body weight at birth.		

378

The limitations of the current study include the self-reported use of tobacco smoking by 379 the pregnant women. Although we had access to nicotine and cotinine levels which made it 380 possible to detect current users, there might be some cases of pregnant women who were 381 382 infrequent smokers as the blood samples were taken as a part of routine visits during the first trimester. We also observed some limitations of self-reporting, i.e., there were 7 383 controls that had to be excluded from the study because of high cotinine levels in these 384 samples. Another limitation is the sample size, which was relatively small and limited the 385 statistical power. For example, with a higher sample size, differences in the levels of sterols 386

387	and lipids could have reached statistical significance (Supplementary table 1). In addition,		
388	the population used for this study was mostly from the Northern Savo area of Finland,		
389	likely with similar lifestyle factors such as their diet. This could explain the increased		
390	abundance of metabolites like paraxanthine which might not be evident in other		
391	populations that do not consume as many caffeinated products. Therefore, a similar study		
392	would need to be done with a different target population. Additionally, for the correlation		
393	analysis, the time between the 1 st trimester samples collection and its linkage to the health		
394	of the newborns, means that many positive and negative changes could have taken place		
395	in the remaining months of the pregnancy. The maternal metabolite profile may have		
396	significantly altered during this time, and this would be reflected in the attained results ⁴² .		
397			
398	In conclusion, the current study successfully compared the differences between smoking		
399	and nonsmoking pregnant women in the circulating metabolome as analyzed from plasma		
400	samples taken in the first trimester. Tobacco smoking during early pregnancy was		
401	associated with alterations in metabolites associated with a disruption of endocrine		
402	functions and increased oxidative stress and linked with a restricted growth of the fetus.		
403	Further studies will need to be conducted in several different populations in order to widen		
404	the generalizability of these results.		

406 Acknowledgements

407	This work was supported	by the Finnish Ministr	y of Social Affairs and Health for the
-----	-------------------------	------------------------	--

- 408 VAURAS project, and the Finnish Foundation for Alcohol Studies. This paper belongs to the
- studies carried out by the Kuopio Birth Cohort consortium (www. KuBiCo.fi) and we thank
- 410 our colleagues who are responsible for the design and conduct of the KuBiCo. We want to
- 411 thank Essi Järvelä for assistance with sample collection, Miia Reponen and Juulia Kuparinen
- for technical assistance with the mass spectrometry analyses, Ewen MacDonald for proof-
- reading, and the staff of the Department of Obstetrics and Gynecology in Kuopio University
- 414 Hospital. The authors also want to thank Biocenter Finland and Biocenter Kuopio for
- supporting the core LC-MS laboratory facility.

416 **Conflict of interest**

- 417 O.K. is a co-founder of Afekta Technologies Ltd. a company providing metabolomics
- 418 analysis services. W.M, T.V, M.L, R.H, S.A, L.K-N, J.R declare no conflicts of interest.

419 **Data Sharing Statement**

420 The data that support the findings of this study are available on request from the

- 421 corresponding author, OK. The study plan approved by the ethical committee and the
- 422 participant consent terms preclude public sharing of these sensitive data, even in

423 anonymized form.

424 References

- Reitan T, Callinan S. Changes in Smoking Rates Among Pregnant Women and the General
 Female Population in Australia, Finland, Norway, and Sweden. *Nicotine Tob Res*.
 2017;19(3):282-289. doi:10.1093/ntr/ntw188
- Havard A, Chandran JJ, Oei JL. Tobacco use during pregnancy. *Addiction*. 2022;117(6):1801 1810. doi:10.1111/add.15792
- Wickström R. Effects of nicotine during pregnancy: human and experimental evidence. *Curr Neuropharmacol.* 2007;5(3):213-222. doi:10.2174/157015907781695955
- 432 4. Kubista E. [Smoking in pregnancy]. *Wien Med Wochenschr*. 1994;144(22-23):529-531.
- 433 5. Rumrich I, Vähäkangas K, Viluksela M, Gissler M, de Ruyter H, Hänninen O. Effects of maternal
 434 smoking on body size and proportions at birth: a register-based cohort study of 1.4 million
 435 births. *BMJ Open*. 2020;10(2):e033465. doi:10.1136/bmjopen-2019-033465
- 436 6. Anderson TM, Lavista Ferres JM, Ren SY, et al. Maternal Smoking Before and During Pregnancy
 437 and the Risk of Sudden Unexpected Infant Death. *Pediatrics*. 2019;143(4):e20183325.
 438 doi:10.1542/peds.2018-3325
- 439 7. Wehby GL, Prater K, McCarthy AM, Castilla EE, Murray JC. The Impact of Maternal Smoking
 440 during Pregnancy on Early Child Neurodevelopment. *J Hum Cap.* 2011;5(2):207-254.
 441 doi:10.1086/660885
- Ino T, Shibuya T, Saito K, Ohtani T. Effects of maternal smoking during pregnancy on body
 composition in offspring. *Pediatr Int*. 2011;53(6):851-857. doi:10.1111/j.1442 200X.2011.03383.x
- Banderali G, Martelli A, Landi M, et al. Short and long term health effects of parental tobacco
 smoking during pregnancy and lactation: a descriptive review. *J Transl Med*. 2015;13:327.
 doi:10.1186/s12967-015-0690-y
- Peacock JL, Palys TJ, Halchenko Y, et al. Assessing tobacco smoke exposure in pregnancy from
 self-report, urinary cotinine and NNAL: a validation study using the New Hampshire Birth
 Cohort Study. *BMJ Open*. 2022;12(2):e054535. doi:10.1136/bmjopen-2021-054535
- LaBarre JL, Puttabyatappa M, Song PXK, et al. Maternal lipid levels across pregnancy impact
 the umbilical cord blood lipidome and infant birth weight. *Sci Rep.* 2020;10(1):14209.
 doi:10.1038/s41598-020-71081-z
- 454 12. Rolle-Kampczyk UE, Krumsiek J, Otto W, et al. Metabolomics reveals effects of maternal
 455 smoking on endogenous metabolites from lipid metabolism in cord blood of newborns.
 456 *Metabolomics*. 2016;12:76. doi:10.1007/s11306-016-0983-z

Tan Y, Barr DB, Ryan PB, et al. High-resolution metabolomics of exposure to tobacco smoke
 during pregnancy and adverse birth outcomes in the Atlanta African American maternal-child
 cohort. *Environ Pollut*. 2022;292(Pt A):118361. doi:10.1016/j.envpol.2021.118361

- 460 14. Donovan MF, Cascella M. Embryology, Weeks 6-8. In: *StatPearls*. StatPearls Publishing; 2024.
 461 Accessed October 14, 2024. http://www.ncbi.nlm.nih.gov/books/NBK563181/
- Huuskonen P, Keski-Nisula L, Heinonen S, et al. Kuopio birth cohort design of a Finnish joint
 research effort for identification of environmental and lifestyle risk factors for the wellbeing of
 the mother and the newborn child. *BMC Pregnancy Childbirth*. 2018;18(1):381.
 doi:10.1186/s12884-018-2013-9
- Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT 2023 policy for
 experimental and clinical studies. *Basic Clin Pharmacol Toxicol*. 2023;133(4):391-396.
 doi:10.1111/bcpt.13944
- 469 17. Voutilainen T, Keski-Nisula L, Rysä J, Kärkkäinen O. Parental cigarette smoking before and
 470 during pregnancy in a cohort of 21 472 pregnancies. *Basic Clin Pharmacol Toxicol*.
 471 2024;134(4):543-555. doi:10.1111/bcpt.13987
- 472 18. Lehikoinen AI, Kärkkäinen OK, Lehtonen MAS, Auriola SOK, Hanhineva KJ, Heinonen ST.
 473 Alcohol and substance use are associated with altered metabolome in the first trimester
 474 serum samples of pregnant mothers. *Eur J Obstet Gynecol Reprod Biol.* 2018;223:79-84.
 475 doi:10.1016/j.ejogrb.2018.02.004
- 476 19. Klåvus A, Kokla M, Noerman S, et al. "notame": Workflow for Non-Targeted LC-MS Metabolic
 477 Profiling. *Metabolites*. 2020;10(4):135. doi:10.3390/metabo10040135
- 478 20. Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for chemical
 479 analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI).
 480 Metabolomics. 2007;3(3):211-221. doi:10.1007/s11306-007-0082-2
- 481 21. Wishart DS, Guo A, Oler E, et al. HMDB 5.0: the Human Metabolome Database for 2022.
 482 *Nucleic Acids Res*. 2022;50(D1):D622-D631. doi:10.1093/nar/gkab1062
- 483 22. Tappin DM, Ford RP, Schluter PJ. Smoking during pregnancy measured by population cotinine
 484 testing. *N Z Med J*. 1997;110(1050):311-314.
- 485 23. Nenezic N, Kostic S, Strac DS, et al. Dehydroepiandrosterone (DHEA): Pharmacological Effects
 486 and Potential Therapeutic Application. *Mini Rev Med Chem*. 2023;23(8):941-952.
 487 doi:10.2174/1389557522666220919125817
- 488 24. Baron JA, Comi RJ, Cryns V, Brinck-Johnsen T, Mercer NG. The effect of cigarette smoking on
 489 adrenal cortical hormones. *J Pharmacol Exp Ther*. 1995;272(1):151-155.
- 490 25. Cora N, Ghandour J, Pollard CM, et al. Nicotine-induced adrenal beta-arrestin1 upregulation
 491 mediates tobacco-related hyperaldosteronism leading to cardiac dysfunction. *World J Cardiol*.
 492 2020;12(5):192-202. doi:10.4330/wjc.v12.i5.192

493 26. Yan Y, Guo F, Liu K, Ding R, Wang Y. The effect of endocrine-disrupting chemicals on placental
494 development. *Front Endocrinol (Lausanne)*. 2023;14:1059854.

- 495 doi:10.3389/fendo.2023.1059854
- 496 27. Kenny LC, SCOPE Consortium, Brown LW, Ortea P, Tuytten R, Kell DB. Relationship between
 497 the concentration of ergothioneine in plasma and the likelihood of developing pre-eclampsia.
 498 *Biosci Rep.* 2023;43(7):BSR20230160. doi:10.1042/BSR20230160
- 28. Smith E, Ottosson F, Hellstrand S, et al. Ergothioneine is associated with reduced mortality and
 decreased risk of cardiovascular disease. *Heart*. 2020;106(9):691-697. doi:10.1136/heartjnl2019-315485
- 502 29. Hinds TD, Stec DE. Bilirubin, a Cardiometabolic Signaling Molecule. *Hypertension*.
 503 2018;72(4):788-795. doi:10.1161/HYPERTENSIONAHA.118.11130
- S04 30. Kodal JB, Çolak Y, Kobylecki CJ, Vedel-Krogh S, Nordestgaard BG, Afzal S. Smoking Reduces
 Plasma Bilirubin: Observational and Genetic Analyses in the Copenhagen General Population
 Study. *Nicotine Tob Res*. 2020;22(1):104-110. doi:10.1093/ntr/nty188
- S1. Kim NH, Kim HC, Lee JY, Lee JM, Suh I. Active and Passive Smoking and Serum Total Bilirubin in
 a Rural Korean Population. *Nicotine Tob Res.* 2016;18(5):572-579. doi:10.1093/ntr/ntv251
- 32. Weaver L, Hamoud AR, Stec DE, Hinds TD. Biliverdin reductase and bilirubin in hepatic
 disease. Am J Physiol Gastrointest Liver Physiol. 2018;314(6):G668-G676.
 doi:10.1152/ajpgi.00026.2018
- S3. Koh M, Ahmad I, Ko Y, et al. A short ORF-encoded transcriptional regulator. *Proc Natl Acad Sci U S A*. 2021;118(4):e2021943118. doi:10.1073/pnas.2021943118
- 514 34. Hamaue N. [Pharmacological role of isatin, an endogenous MAO inhibitor]. Yakugaku Zasshi.
 515 2000;120(4):352-362. doi:10.1248/yakushi1947.120.4_352
- S16 35. Buneeva OA, Kapitsa IG, Kazieva LS, Vavilov NE, Zgoda VG. Quantitative changes of brain
 isatin-binding proteins of rats with the rotenone-induced experimental parkinsonism. *Biomed Khim*. 2023;69(3):188-192. doi:10.18097/PBMC20236903188
- 36. Bowker K, Lewis S, Coleman T, Cooper S. Changes in the rate of nicotine metabolism across
 pregnancy: a longitudinal study. *Addiction*. 2015;110(11):1827-1832. doi:10.1111/add.13029
- 37. Qian J, Chen Q, Ward SM, Duan E, Zhang Y. Impacts of Caffeine during Pregnancy. *Trends Endocrinol Metab.* 2020;31(3):218-227. doi:10.1016/j.tem.2019.11.004
- 38. Yu T, Campbell SC, Stockmann C, et al. Pregnancy-induced changes in the pharmacokinetics
 of caffeine and its metabolites. *J Clin Pharmacol*. 2016;56(5):590-596. doi:10.1002/jcph.632
- 525 39. Hey E. Coffee and pregnancy. *BMJ*. 2007;334(7590):377. doi:10.1136/bmj.39122.395058.80

- 40. Jin F, Qiao C. Association of maternal caffeine intake during pregnancy with low birth weight,
- 527 childhood overweight, and obesity: a meta-analysis of cohort studies. *Int J Obes (Lond)*.
- 528 2021;45(2):279-287. doi:10.1038/s41366-020-0617-4
- 41. Huffman SL, Harika RK, Eilander A, Osendarp SJM. Essential fats: how do they affect growth
- and development of infants and young children in developing countries? A literature review.
- 531
 Matern Child Nutr. 2011;7 Suppl 3(Suppl 3):44-65. doi:10.1111/j.1740-8709.2011.00356.x
- 42. Jääskeläinen T, Kärkkäinen O, Jokkala J, et al. A non-targeted LC-MS metabolic profiling of
- 533 pregnancy: longitudinal evidence from healthy and pre-eclamptic pregnancies. *Metabolomics*.
- 534 2021;17(2):20. doi:10.1007/s11306-020-01752-5